Trial intelligence / Profile preview

Phase 2 randomized placebo-controlled study of subcutaneous ARGX-121 in adults with primary IgA nephropathy

MOH_2026-08-26_017010Phase 2Not yet recruiting

Sponsor: argenx
Start: Aug 2026
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, randomised, double-blind trial in IgA nephropathy (IgAN) comparing ARGX-121 → ARGX-121 with Placebo → ARGX-121 (2 arms). Planned start Aug 2026; status: not yet recruiting.

Drugs

ARGX-121

Conditions

IgA nephropathy (IgAN)

Beyond the preview

Go deeper on MOH_2026-08-26_017010.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on MOH_2026-08-26_017010.